Suchergebnisse
UB Katalog
Artikel & mehr
Suchmaske
Suchergebnisse einschränken oder erweitern
Aktive Suchfilter
Weniger Treffer
Gefunden in
Art der Quelle
Schlagwort
- cancer -- care and treatment 62 Treffer
- immunotherapy 43 Treffer
- product development 42 Treffer
- biological products industry 41 Treffer
- biological products industry -- product development 41 Treffer
-
45 weitere Werte:
- cel-sci corp. -- product development 40 Treffer
- cel-sci corp. 39 Treffer
- clinical trials 38 Treffer
- drug therapy 18 Treffer
- head and neck cancer 17 Treffer
- cancer 15 Treffer
- pharmaceutical industry -- product development 12 Treffer
- cancer -- drug therapy 9 Treffer
- stockholders 9 Treffer
- cancer research 8 Treffer
- head and neck cancer -- drug therapy 8 Treffer
- biological products industry -- intellectual property 7 Treffer
- intellectual property 7 Treffer
- medical research 7 Treffer
- medicine, experimental 7 Treffer
- patent/copyright issue 7 Treffer
- patents 7 Treffer
- antimitotic agents 6 Treffer
- antineoplastic agents 6 Treffer
- cel-sci corp. -- intellectual property 6 Treffer
- teva pharmaceutical industries ltd. -- product development 6 Treffer
- oncology, experimental 5 Treffer
- cancer -- care and treatment -- research 4 Treffer
- care and treatment 4 Treffer
- health 4 Treffer
- united states. food and drug administration 4 Treffer
- cancer -- care and treatment -- drug therapy 3 Treffer
- biological products industry -- licensing agreements 2 Treffer
- cel-sci corp. -- licensing agreements 2 Treffer
- cholesterol 2 Treffer
- company licensing agreement 2 Treffer
- head and neck cancer -- care and treatment 2 Treffer
- interleukins 2 Treffer
- licensing agreements 2 Treffer
- pharmaceutical industry -- licensing agreements 2 Treffer
- pharmaceuticals and cosmetics industries 2 Treffer
- radiotherapy 2 Treffer
- science and technology 2 Treffer
- teva pharmaceutical industries ltd. -- licensing agreements 2 Treffer
- universities and colleges -- united states -- illinois 2 Treffer
- afatinib 1 Treffer
- aids (disease) 1 Treffer
- aids vaccines 1 Treffer
- alternative energy sources 1 Treffer
- antimitotic agents -- licensing agreements 1 Treffer
Verlag
Publikation
- business wire 49 Treffer
- m2 communications 7 Treffer
- india pharma news 6 Treffer
- accesswire 5 Treffer
- contify life science news 4 Treffer
-
17 weitere Werte:
- midnighttrader live briefs 3 Treffer
- plus company updates 3 Treffer
- daily the pak banker (lahore, pakistan) 2 Treffer
- m2 equitybites (eqb) 2 Treffer
- plus news 2 Treffer
- thomson reuters one 2 Treffer
- aids vaccine week 1 Treffer
- aids weekly 1 Treffer
- benzinga.com 1 Treffer
- biotech week 1 Treffer
- cancer vaccine week 1 Treffer
- immunotherapy weekly 1 Treffer
- m2 presswire 1 Treffer
- plus financial reports 1 Treffer
- right vision news 1 Treffer
- rtt news 1 Treffer
- us official news 1 Treffer
Sprache
96 Treffer
-
-
Amgen Phase III Immunotherapy Trials Fail; CVM Last Player On Deck This Year (AMGN, TEVA, DNDN, CVM)In: Benzinga.com, 2010-08-16ZeitungsartikelZugriff:
-
In: M2 Presswire, 2011-04-11ZeitungsartikelZugriff:
-
In: M2 Communications, 2011-04-11ZeitungsartikelZugriff:
-
In: M2 Communications, 2010-05-05ZeitungsartikelZugriff:
-
OTCMarketBulls: OTCMarketbulls.com Brings You the HOTTEST gainers! Sign Up Today!! RZ, BPZ, CVM, MSOIn: M2 Communications, 2010-02-17ZeitungsartikelZugriff:
-
In: Business Wire, 2024-03-06ZeitungsartikelZugriff:
-
In: Plus Company Updates, 2022-09-08ZeitungsartikelZugriff:
-
In: Business Wire, 2022-04-22ZeitungsartikelZugriff:
-
In: Contify Life Science News, 2021-01-04ZeitungsartikelZugriff:
-
In: Business Wire, 2021-01-04ZeitungsartikelZugriff:
-
In: Plus Company Updates, 2020-12-15ZeitungsartikelZugriff:
-
In: Contify Life Science News, 2020-12-14ZeitungsartikelZugriff:
-
In: Business Wire, 2020-12-14ZeitungsartikelZugriff:
-
In: Plus Company Updates, 2020-09-16ZeitungsartikelZugriff:
-
In: Contify Life Science News, 2020-09-15ZeitungsartikelZugriff:
-
In: Contify Life Science News, 2020-09-11ZeitungsartikelZugriff:
-
In: Business Wire, 2020-09-11ZeitungsartikelZugriff:
-
In: ACCESSWIRE, 2020-08-31ZeitungsartikelZugriff: